DSIP (Delta Sleep-Inducing Peptide)
Mechanism, Benefits, Dosing, & Research 2026
DSIP is a naturally occurring peptide your brain already produces — one linked to the deepest, most restorative phase of sleep. Researchers have studied it since 1977, and a small number of human trials show it can meaningfully improve sleep depth without acting like a sedative. The clinical evidence is limited, the regulatory situation in the US is still evolving, and long-term human safety data does not exist. This guide covers what the research actually shows, how dosing protocols are structured, and where DSIP currently stands legally.
Key takeaways
- DSIP promotes deep slow-wave sleep (NREM Stage 3) by modulating your sleep-wake cycle — not by sedating you the way sleeping pills do.
- A 1981 human study (Schneider-Helmert et al., PMID 6895513) found a 59% increase in total sleep time after IV DSIP infusion in six healthy volunteers.
- DSIP was placed on the FDA’s Category 2 bulk drug substance list in 2023, but a February 2026 HHS announcement signaled an expected reclassification to Category 1, which would restore compounding pharmacy access with a physician’s prescription.
- PeptideRx rates the evidence for DSIP’s sleep-promoting effects as Grade C: primarily older human studies with small sample sizes, supported by animal data and a plausible mechanism.
- Competitive athletes subject to WADA or USADA testing should not use DSIP — it falls under WADA’s S0 category (non-approved substances).
Before you start All peptide protocols require a physician evaluation. DSIP has no long-term human safety data — the longest published human study ran approximately two weeks — and its interaction with sedatives and CNS depressants warrants clinical review before use.
What is DSIP?
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid neuropeptide (sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) your hypothalamus produces naturally. Its molecular weight is 848.81 g/mol.
Schoenenberger and Monnier at the University of Basel first isolated DSIP in 1977 from the cerebral venous blood of rabbits during electrically induced slow-wave sleep (PMID 265577). Since then, researchers have detected DSIP in the limbic system, pituitary gland, and various peripheral organs. It also appears in human breast milk at concentrations of 10–30 ng/mL.
DSIP concentrations in your blood follow a daily rhythm: low in the morning, rising through the afternoon. This circadian pattern aligns with its proposed role in sleep regulation.
One genuinely unusual fact: DSIP is the only known neuropeptide whose encoding gene has not been identified. Researchers know the amino acid sequence but have not found the gene responsible for producing it — an open question that makes DSIP biologically unusual.
Learn more about how neuropeptides influence sleep architecture.
How does DSIP work?
DSIP doesn’t knock you out. That distinction matters.
Sleep researchers classify DSIP as a “sleep-promoting substance” rather than a sedative. It modulates the sleep-wake cycle, meaning its effects are most pronounced when sleep is already disturbed. In people with normal sleep patterns, changes are minimal.
Here’s how the signaling chain works:
DSIP crosses the blood-brain barrier → interacts with GABAergic and HPA axis systems → reduces cortisol secretion → promotes slow-wave (NREM Stage 3) sleep
Most peptides can’t cross the blood-brain barrier (BBB). DSIP is an exception, likely because of its amphiphilic properties — it’s both water-soluble and lipid-soluble — combined with binding to carrier proteins that protect it during transit.
Once past the BBB, DSIP has a half-life of approximately 15 minutes. It degrades quickly when exposed to brain enzymes. That short window explains why dosing protocols target the 30–60 minutes before sleep.
What DSIP does at the system level
DSIP influences two key systems:
GABAergic signaling — GABA is the brain’s primary inhibitory neurotransmitter. Benzodiazepines also target this system, but DSIP’s interaction appears to differ: no documented dependency has been associated with DSIP in the published literature.
The HPA axis — The hypothalamic-pituitary-adrenal (HPA) axis controls your body’s stress response through cortisol, corticotropin-releasing hormone (CRH), and adrenocorticotropic hormone (ACTH). DSIP modulates this axis, reducing cortisol secretion. Chronic HPA overactivation — elevated cortisol — disrupts sleep, impairs immune function, and is associated with accelerated aging.
DSIP also influences growth hormone secretion, but not directly. Any GH increase from DSIP is a downstream effect of deeper slow-wave sleep, which is the sleep phase when the body naturally releases the most growth hormone. DSIP is not a growth hormone secretagogue.
Learn more about how the HPA axis affects sleep quality.
What does the research show?
Key takeaways — research
- The strongest human evidence comes from two 1981 Schneider-Helmert studies showing improved sleep duration and quality in both healthy volunteers and chronic insomnia patients.
- A 1992 double-blind trial (Bes et al., PMID 1299794) found statistically significant improvements in sleep efficiency and latency — with the caveat that effects were modest.
- All human trials used sample sizes of 6–16 participants. No modern randomized controlled trials have been published.
Sleep architecture: slow-wave sleep and delta-wave activity
The 1981 Schneider-Helmert study (PMID 6895513) administered 25 nmol/kg of DSIP intravenously to six healthy volunteers. Total sleep time increased by 59% within 130 minutes compared to placebo, and subjects reported immediate sleep pressure. Effects extended to the following night — shorter sleep onset and improved sleep efficiency — with no daytime sedation observed.
A separate 1981 study (Schneider-Helmert and Schoenenberger, PMID 7028502) tested DSIP in six chronic insomnia patients. Results showed longer sleep duration, fewer interruptions, and higher sleep quality. A slight arousing effect appeared in the first hour after injection — consistent with DSIP’s modulatory mechanism — followed by sleep promotion in the second hour.
A 1992 double-blind study (Bes et al., PMID 1299794) in 16 chronic insomnia patients found statistically significant improvements in sleep efficiency and sleep latency versus placebo. The authors noted that effects were modest and partly attributable to variation in the placebo group.
Data gap: All human sleep studies for DSIP were conducted between 1981 and 1992, with sample sizes of 6–16 participants. No modern randomized controlled trials exist.
Stress and HPA axis adaptation
Animal studies (Sudakov et al., 1995 and 2005, PMID 16180303) showed DSIP increased resistance to emotional stress by modulating hypothalamic neuropeptide levels. Specifically, DSIP raised substance P concentration in the hypothalamus of stressed rats — a marker associated with improved stress coping. Effects occurred without sedation.
Pain modulation
DSIP has shown antinociceptive (pain-reducing) effects in animal models through interaction with opioid receptor pathways, specifically beta-endorphin modulation. This mechanism appears distinct from traditional analgesics and does not involve direct opioid receptor agonism. No human pain trials have been published.
Neuroprotection
A 2023 study (Tukhovskaya et al.) found that a DSIP analogue called KND reduced brain infarction size in mice during reperfusion and reduced myocardial infarction in rats. DSIP analogues have also shown antioxidant properties and mitochondrial respiration support in preclinical models. This research is entirely preclinical.
Mood and depression
Walleus et al. (1985) reported decreased DSIP concentrations in plasma and cerebrospinal fluid from depressed patients. Westrin et al. (1998) found elevated DSIP-like immunoreactivity in suicidal patients with major depressive disorder. Whether low DSIP contributes to depression or depression suppresses DSIP production remains unclear.
Learn more about peptides studied for stress and HPA axis modulation.
Dosing and administration
Published research protocols used 25 nmol/kg intravenously — approximately 20–50 mcg for a 70 kg person. Community protocols use higher subcutaneous doses (100–300 mcg), reflecting the different absorption profile of subcutaneous versus IV delivery. No published study has validated specific subcutaneous doses.
Start at 100 mcg and increase by 50–100 mcg every 3–5 days based on response. Administer on an empty stomach 30–60 minutes before sleep.
Dosing by goal
| Goal | Route | Dose | Frequency | Cycle duration | Evidence basis |
|---|---|---|---|---|---|
| Chronic insomnia (sleep depth) | Subcutaneous injection | 200–300 mcg | Nightly, 30–60 min pre-sleep | 2–4 weeks on, 1–2 weeks off | Adapted from research protocols |
| Stress and sleep support | Subcutaneous injection | 100–200 mcg | 3–5 nights per week | 2–4 weeks on, 1–2 weeks off | Extrapolated from animal stress data |
| Acute insomnia (short-term) | SC or intranasal | 100–200 mcg | As needed (2–3 nights/week) | 1–2 weeks | Low-dose adapted from Schneider-Helmert |
| Performance recovery | Subcutaneous injection | 200–300 mcg | Nightly during recovery phase | 2 weeks max | Theoretical; no direct study |
Administration routes compared
| Route | Estimated bioavailability | Typical dose range | Onset | Key notes |
|---|---|---|---|---|
| Subcutaneous injection | High | 100–300 mcg | 30–60 min | Most consistent absorption; aligns with research settings |
| Intranasal spray | Moderate (variable) | 200–500 mcg | 15–30 min | Convenient; less predictable dosing |
| Sublingual | Low–moderate | 300–500 mcg | 20–40 min | Limited data; some peptide degradation in oral mucosa |
| Oral | Very low | Not recommended | Variable | Significant GI degradation expected; no bioavailability data published |
Subcutaneous injection provides the most consistent absorption and aligns most closely with published research protocols.
Reconstitution guide
| Vial size | Bacteriostatic water volume | Concentration | Volume for 200 mcg dose | Volume for 300 mcg dose |
|---|---|---|---|---|
| 2 mg | 2 mL | 1,000 mcg/mL | 0.2 mL (20 units) | 0.3 mL (30 units) |
| 5 mg | 2 mL | 2,500 mcg/mL | 0.08 mL (8 units) | 0.12 mL (12 units) |
| 5 mg | 5 mL | 1,000 mcg/mL | 0.2 mL (20 units) | 0.3 mL (30 units) |
Inject bacteriostatic water slowly along the inner wall of the vial. Swirl gently until dissolved. Do not shake.
Storage:
- Lyophilized (unreconstituted): -20°C for long-term; 2–8°C acceptable for weeks to months.
- Reconstituted with bacteriostatic water: Refrigerate at 2–8°C. Use within 2–4 weeks.
- Reconstituted with sterile water: Refrigerate at 2–8°C. Use within 3–5 days.
Never freeze reconstituted DSIP. Protect from light.
Injection technique: Use a 28–31 gauge insulin syringe with a 5–8 mm needle. Pinch skin at the abdomen (preferred), upper thigh, or back of arm. Insert at a 45-degree angle and inject slowly. Rotate injection sites daily to avoid lipohypertrophy.
Cycling
A 2–4 week on, 1–2 week off cycle is widely reported in the peptide community, with the rationale of preventing potential downregulation of endogenous DSIP production. No published study has confirmed whether this actually occurs.
Learn more about subcutaneous peptide injection technique.
Side effects and safety
Important: No documented cases of DSIP dependence, withdrawal, or overdose exist in the published literature. The longest published human study ran approximately two weeks. No data exists on months or years of use.
Commonly reported side effects
| Side effect | Estimated frequency | Notes |
|---|---|---|
| Vivid dreams | 10–30% of users (community-reported) | Generally described as neutral or positive |
| Next-day grogginess | More common at higher doses | More likely with late-night dosing |
| Mild headache | Occasional | More common with intranasal delivery |
| Injection site reaction | Variable | Redness, mild irritation with SC administration |
Theoretical concerns (unconfirmed in humans)
HPA axis suppression — DSIP modulates cortisol. Long-term use could theoretically alter endogenous cortisol regulation. Not confirmed in human studies.
Endocrine effects — DSIP influences LH and GH secretion at the hypothalamic level. Long-term impact on endocrine function has not been studied.
No mechanism links DSIP to angiogenesis or tumor promotion. No case reports of cancer association exist in the literature.
Contraindications
- Pregnancy and breastfeeding (DSIP is naturally present in breast milk, but effects of exogenous administration during pregnancy are unknown)
- Concurrent use of strong sedatives or CNS depressants (risk of additive sedation)
- Severe psychiatric conditions (effects on mood-related neuropeptides are not fully characterized)
- Untreated obstructive sleep apnea (deepened sleep without treating the airway obstruction could worsen apnea events)
Learn more about peptide safety considerations and monitoring.
Legal status (2026)
DSIP is not FDA-approved for human therapeutic use.
In 2023, the FDA placed DSIP (listed as Emideltide/DSIP/Delta Sleep-Inducing Peptide) on the Category 2 bulk drug substance list, restricting compounding pharmacies from preparing it under Section 503A regulations.
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the Category 2 list — including DSIP — are expected to be reclassified to Category 1. As of March 2026, the FDA has not published its formal updated list. If reclassification is formalized, licensed compounding pharmacies would again be able to prepare DSIP with a physician’s prescription.
Important: DSIP is currently sold as a research chemical labeled “for research use only.” Personal possession carries low enforcement risk in the United States, but using a research chemical as a drug technically violates the Federal Food, Drug, and Cosmetic Act.
WADA status: DSIP is not specifically named on the 2026 WADA Prohibited List, but falls under the S0 category, which prohibits all pharmacological substances without current governmental regulatory health authority approval for human therapeutic use. Any athlete subject to WADA or USADA testing should avoid DSIP.
International status: DSIP is not formally approved in the EU, UK, Canada, or Australia. Importing peptides across international borders may carry legal risk depending on destination country regulations.
Learn more about the 2026 FDA peptide reclassification timeline.
Alternatives to DSIP
The right sleep support depends on what’s actually causing the problem. DSIP targets sleep depth. Melatonin targets sleep timing. Selank targets anxiety that prevents sleep onset. CJC-1295/Ipamorelin targets growth hormone release. These are distinct mechanisms.
For people who have not tried first-line options, melatonin (0.5–3 mg), magnesium glycinate (200–400 mg), and sleep hygiene improvements should be attempted before considering research peptides.
| Compound | Primary mechanism | Best for | Evidence base | Approx. cost/month | Legal status (US, 2026) |
|---|---|---|---|---|---|
| DSIP | Slow-wave sleep promotion; HPA axis modulation | Sleep depth; stress-related sleep disruption | Small human studies (1980s–90s); animal data | $30–60 (research grade) | Research chemical; Category 2 (reclassification to Cat 1 expected) |
| Selank | GABA/serotonin modulation; anxiolytic | Anxiety-driven insomnia; stress | Human studies (Russia); limited Western replication | $30–50 | Research chemical; expected Cat 1 reclassification |
| Epitalon | Telomerase activation; pineal gland melatonin support | Anti-aging; circadian rhythm restoration | Limited human trials; animal data | $40–80 | Research chemical; Category 2 (expected Cat 1 reclassification) |
| CJC-1295/Ipamorelin | Growth hormone secretion stimulation | GH increase; body composition; indirect sleep benefit | Human studies (GH endpoints) | $60–120 | Research chemical; regulatory status varies |
| Melatonin | Circadian rhythm timing; SCN signaling | Jet lag; delayed sleep phase; sleep onset | Extensive human trials; FDA-recognized supplement | $5–15 | OTC dietary supplement |
| Magnesium glycinate | GABA receptor modulation; muscle relaxation | General sleep support; magnesium deficiency | Human studies (sleep quality endpoints) | $10–20 | OTC dietary supplement |
No head-to-head comparison trial has been conducted between DSIP and any of these alternatives.
Learn more about peptide options for sleep and stress support.
The bottom line
DSIP is one of the more scientifically interesting sleep peptides, mainly because its mechanism is genuinely different from anything in the standard sleep medicine toolkit. It promotes deep sleep architecture rather than sedating you — a distinction your body notices. The human evidence is real but old and limited: a handful of small trials from the 1980s and 1990s showing meaningful improvements in sleep duration and quality, with no major safety signals in short-term use.
If you’re considering DSIP, the honest summary is this: the mechanism is plausible, the early human data is moderately encouraging, and the side effect profile looks manageable based on what exists. What doesn’t exist is long-term data. For sleep problems with a clear anxiety or timing component, first-line options like melatonin, magnesium glycinate, and behavioral interventions have far more evidence behind them. If you’ve worked through those and your sleep quality — particularly sleep depth — remains the issue, a conversation with a licensed physician about DSIP and the evolving compounding pharmacy pathway makes sense.
Frequently Asked Questions
What is the standard DSIP dosage for subcutaneous injection?
Commonly reported dosing in clinical protocols ranges from 200–300 mcg subcutaneously, administered 30–60 minutes before sleep. Starting at 100 mcg and titrating upward by 50–100 mcg every 3–5 days is a reasonable approach. Published research used lower IV doses (approximately 20–50 mcg for a 70 kg person), but intravenous and subcutaneous delivery have different absorption profiles, which is why community protocols use higher SC doses.
How long does reconstituted DSIP last after mixing?
DSIP reconstituted with bacteriostatic water lasts 2–4 weeks refrigerated at 2–8°C. DSIP reconstituted with sterile water (no preservative) lasts 3–5 days refrigerated. Do not freeze reconstituted DSIP.
Is DSIP legal to purchase in the United States?
Yes, with important caveats. DSIP is sold as a research chemical and can be purchased for research purposes. Personal possession carries low enforcement risk, but using a research chemical as a drug technically violates the Federal Food, Drug, and Cosmetic Act. A compounding pharmacy pathway with a physician’s prescription may become available if the expected reclassification from Category 2 to Category 1 is formalized by the FDA.
Can competitive athletes use DSIP?
No. DSIP falls under WADA’s S0 category, which covers all non-approved pharmacological substances regardless of whether they appear by name on the prohibited list. Any athlete subject to WADA or USADA testing should avoid DSIP.
What are the most common DSIP side effects?
Vivid dreams (reported by an estimated 10–30% of users), next-day grogginess — particularly at higher doses or with late-night dosing — and occasional mild headache are the most commonly reported effects. Injection site reactions such as redness and mild irritation may occur with subcutaneous administration. No documented cases of dependence or withdrawal appear in the published literature.
How do you reconstitute a 2 mg DSIP vial?
Add 2 mL of bacteriostatic water to a 2 mg vial to produce a concentration of 1,000 mcg/mL. A 200 mcg dose equals 0.2 mL (20 units on an insulin syringe); a 300 mcg dose equals 0.3 mL (30 units). Inject the water slowly along the vial wall and swirl gently — do not shake.
Does DSIP increase growth hormone?
Not directly. DSIP is not a growth hormone secretagogue. Any growth hormone increase associated with DSIP is an indirect effect of more time spent in deep slow-wave sleep — the phase when the body naturally releases the most GH. If increasing growth hormone is your primary goal, CJC-1295/Ipamorelin and similar GH secretagogues target that pathway directly.
Can DSIP be stacked with melatonin?
Yes. DSIP and melatonin work through complementary mechanisms: melatonin regulates when you fall asleep (circadian timing), while DSIP influences how deeply you sleep (slow-wave architecture). A typical combination uses 200–300 mcg DSIP alongside 0.5–3 mg melatonin, both taken 30–60 minutes before sleep. No formal drug interaction study has been conducted on this combination.
Considering peptide therapy for sleep? Speak with a licensed physician who can review your sleep history and discuss whether any evidence-based option is appropriate for your situation.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282–1286. PMID: 265577.
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341–345. PMID: 6895513.
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981;37(9):913–917. PMID: 7028502.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83–93. PMID: 6152961.
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;26(4):193–197. PMID: 1299794.
- Sudakov KV, et al. Delta-sleep inducing peptide sequels in mechanisms of resistance to emotional stress. Ann N Y Acad Sci. 1995;771:240–251.
- Sudakov KV, et al. (2005). PMID: 16180303.
- Iyer KS, McCann SM. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain Res Bull. 1987;19(5):535–538. PMID: 3121137.
- Tukhovskaya EA, et al. DSIP-like KND peptide reduces brain infarction in C57Bl/6 and reduces myocardial infarction in SD rats when administered during reperfusion. Molecules. 2023.
- Walleus H, Widerlöv E, Ekman R. Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients. Nordic J Psychiatry. 1985;39:63–67.
- Delta sleep-inducing peptide [review]. Eur J Anaesthesiol. 2001;18(7):413–417.
Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy. PeptideRx does not provide medical advice, diagnosis, or treatment. DSIP is not FDA-approved for human therapeutic use. DSIP is classified as a Category 2 bulk drug substance as of March 2026, with reclassification to Category 1 expected but not yet formalized. All dosing information reflects published research protocols and community-reported practices, not prescribing recommendations. DSIP falls under WADA’s S0 category. Competitive athletes should not use DSIP. Consult a licensed healthcare provider before making any decisions about peptide therapy. Content medically reviewed [date]. Evidence grading criteria are working definitions pending formal review.